BACKGROUND: The CpG island methylator phenotype (CIMP), characterised by widespread promoter methylation, is associated with microsatellite instability (MSI) and BRAF mutation in colorectal cancer. The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain. METHODS: Utilising 649 colon cancers (stage I-IV) in two independent cohort studies, we quantified DNA methylation in eight CIMP-specific promoters (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) as well as CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN by using MethyLight technology. We examined MSI, KRAS and BRAF status. Cox proportional hazard models computed hazard ratios (HRs) for colon cancer-specific and overall mortalities, adjusting for patient characteristics and tumoral molecular features. RESULTS: After adjustment for other predictors of patient survival, patients with CIMP-high cancers (126 (19%) tumours with >or=6/8 methylated CIMP-specific promoters) experienced a significantly low colon cancer-specific mortality (multivariate HR 0.44, 95% confidence interval (CI) 0.22 to 0.88), whereas the BRAF mutation was significantly associated with a high cancer-specific mortality (multivariate HR 1.97, 95% CI 1.13 to 3.42). A trend toward a low cancer-specific mortality was observed for MSI-high tumours (multivariate HR 0.70, 95% CI 0.36 to 1.37). In stratified analyses, CIMP-high tumours were associated with a significant reduction in colon cancer-specific mortality, regardless of both MSI and BRAF status. The relation between CIMP-high and lower mortality appeared to be consistent across all stages. KRAS mutation was unrelated to prognostic significance. CONCLUSION: CIMP-high appears to be an independent predictor of a low colon cancer-specific mortality, while BRAF mutation is associated with a high colon cancer-specific mortality.
BACKGROUND: The CpG island methylator phenotype (CIMP), characterised by widespread promoter methylation, is associated with microsatellite instability (MSI) and BRAF mutation in colorectal cancer. The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain. METHODS: Utilising 649 colon cancers (stage I-IV) in two independent cohort studies, we quantified DNA methylation in eight CIMP-specific promoters (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) as well as CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN by using MethyLight technology. We examined MSI, KRAS and BRAF status. Cox proportional hazard models computed hazard ratios (HRs) for colon cancer-specific and overall mortalities, adjusting for patient characteristics and tumoral molecular features. RESULTS: After adjustment for other predictors of patient survival, patients with CIMP-high cancers (126 (19%) tumours with >or=6/8 methylated CIMP-specific promoters) experienced a significantly low colon cancer-specific mortality (multivariate HR 0.44, 95% confidence interval (CI) 0.22 to 0.88), whereas the BRAF mutation was significantly associated with a high cancer-specific mortality (multivariate HR 1.97, 95% CI 1.13 to 3.42). A trend toward a low cancer-specific mortality was observed for MSI-high tumours (multivariate HR 0.70, 95% CI 0.36 to 1.37). In stratified analyses, CIMP-high tumours were associated with a significant reduction in colon cancer-specific mortality, regardless of both MSI and BRAF status. The relation between CIMP-high and lower mortality appeared to be consistent across all stages. KRAS mutation was unrelated to prognostic significance. CONCLUSION:CIMP-high appears to be an independent predictor of a low colon cancer-specific mortality, while BRAF mutation is associated with a high colon cancer-specific mortality.
Authors: Vicki L J Whitehall; Coral V A Wynter; Michael D Walsh; Lisa A Simms; David Purdie; Nirmala Pandeya; Joanne Young; Stephen J Meltzer; Barbara A Leggett; Jeremy R Jass Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird Journal: Nucleic Acids Res Date: 2000-04-15 Impact factor: 16.971
Authors: T Kambara; L A Simms; V L J Whitehall; K J Spring; C V A Wynter; M D Walsh; M A Barker; S Arnold; A McGivern; N Matsubara; N Tanaka; T Higuchi; J Young; J R Jass; B A Leggett Journal: Gut Date: 2004-08 Impact factor: 23.059
Authors: Marius Van Rijnsoever; Hany Elsaleh; David Joseph; Kieran McCaul; Barry Iacopetta Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: E Domingo; P Laiho; M Ollikainen; M Pinto; L Wang; A J French; J Westra; T Frebourg; E Espín; M Armengol; R Hamelin; H Yamamoto; R M W Hofstra; R Seruca; A Lindblom; P Peltomäki; S N Thibodeau; L A Aaltonen; S Schwartz Journal: J Med Genet Date: 2004-09 Impact factor: 6.318
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: NaNa Keum; Chen Yuan; Reiko Nishihara; Emilie Zoltick; Tsuyoshi Hamada; Alejandro Martinez Fernandez; Xuehong Zhang; Akiko Hanyuda; Li Liu; Keisuke Kosumi; Jonathan A Nowak; Iny Jhun; T Rinda Soong; Teppei Morikawa; Fred K Tabung; Zhi Rong Qian; Charles S Fuchs; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Shuji Ogino; Edward L Giovannucci; Kana Wu Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: Akiko Hanyuda; Yin Cao; Tsuyoshi Hamada; Jonathan A Nowak; Zhi Rong Qian; Yohei Masugi; Annacarolina da Silva; Li Liu; Keisuke Kosumi; Thing Rinda Soong; Iny Jhun; Kana Wu; Xuehong Zhang; Mingyang Song; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Reiko Nishihara Journal: Eur J Epidemiol Date: 2017-05-16 Impact factor: 8.082
Authors: Li Liu; Reiko Nishihara; Zhi Rong Qian; Fred K Tabung; Daniel Nevo; Xuehong Zhang; Mingyang Song; Yin Cao; Kosuke Mima; Yohei Masugi; Yan Shi; Annacarolina da Silva; Tyler Twombly; Mancang Gu; Wanwan Li; Tsuyoshi Hamada; Keisuke Kosumi; Kentaro Inamura; Jonathan A Nowak; David A Drew; Paul Lochhead; Katsuhiko Nosho; Kana Wu; Molin Wang; Wendy S Garrett; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino Journal: Gastroenterology Date: 2017-09-01 Impact factor: 22.682
Authors: Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245